131I-lipiodol

131I-lipiodol (Lipiocis) is an investigational radiopharmaceutical agent developed for the adjuvant treatment of hepatocellular carcinoma (HCC). It consists of the radioactive isotope iodine-131 covalently bound to lipiodol, an iodinated poppyseed oil contrast medium. Lipiodol is characterized by its ability to be selectively retained within the microvasculature and extracellular space of hepatic tumors following intra-arterial injection. This selective uptake allows for the targeted delivery of high-energy beta particles from the iodine-131 directly to the tumor site, inducing DNA damage and cell death while minimizing radiation exposure to healthy liver tissue. The drug is primarily investigated for use after curative interventions, such as surgical resection or radiofrequency ablation, to eliminate residual micrometastases and prevent tumor recurrence. Clinical development has been significantly supported by ANRS Emerging Infectious Diseases.

Brand names

Lipiocis

Other names

131I-labeled lipiodolradioactive lipiodoliodine-131-labeled lipiodoliodine131-labeled lipiodoliodine 131-labeled lipiodolLipiocis-ANRS